http://www.w3.org/ns/prov#value | - The gross proceeds to Cancer Genetics from the initial public offering are expected to be $6,000,000 (assuming no exercise of the over-allotment option), before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.
|